249 related articles for article (PubMed ID: 24556630)
1. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
Ung N; Putoczki TL; Stylli SS; Ng I; Mariadason JM; Chan TA; Zhu HJ; Luwor RB
Cancer Biol Ther; 2014 May; 15(5):623-32. PubMed ID: 24556630
[TBL] [Abstract][Full Text] [Related]
2. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.
Lu Y; Shi C; Qiu S; Fan Z
Oncotarget; 2016 Oct; 7(40):64766-64777. PubMed ID: 27074568
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
[TBL] [Abstract][Full Text] [Related]
6. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Jhawer M; Goel S; Wilson AJ; Montagna C; Ling YH; Byun DS; Nasser S; Arango D; Shin J; Klampfer L; Augenlicht LH; Perez-Soler R; Mariadason JM
Cancer Res; 2008 Mar; 68(6):1953-61. PubMed ID: 18339877
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
10. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL
Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198
[TBL] [Abstract][Full Text] [Related]
11. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
12. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
[TBL] [Abstract][Full Text] [Related]
17. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
19. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
[TBL] [Abstract][Full Text] [Related]
20. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
